Novalis LifeSciences Launches Second Life Science Investment Fund with $300M

Novalis LifeSciences LLC, a Hampton, N.H.-based investment and advisory firm for the Life Science industry, raised $300M in capital for its second fund – Novalis LifeSciences Investments II, LP.

This second fund will continue with the investment strategy of Fund I. It will invest in 10-15 companies that are commercializing breakthrough technologies in various segments of the Life Science industry. These segments include biopharma therapeutics, life science tools, genomics, synthetic biology, molecular diagnostics, and agricultural biotechnology – all areas with huge unmet needs and exciting opportunities for investors.

Some key portfolio companies of Fund I are Ginkgo Bioworks, Cerevel Therapeutics, Decipher Biosciences, Quanterix, and Biotalys, all of which recently became public companies or were acquired.

Led by Marijn E. Dekkers, founder and chairman, and Paul M. Meister, partner, Constantine G. Pantelis, Chief Operating Officer, and Devin Leake, Managing Director, the firm has approximately $500M under management in two investment funds.